Newsweek Men's Journal Genlux Newsweek Fox 11 UCLA Anderson Men's Journal Brentwood News FOX 11 ABC PR Newswire Men's Journal
Virtual Second Opinion Presidential Physical Membership Options

Health. Care. Unequaled.

Aspirin Response Test™

25% of patients on aspirin therapy receive little or no benefit!

ART™ is an enzyme-linked immunoassay (ELISA) used to determine levels of 11-dehydro thromboxane B2 (11dhTxB2) in human urine, which aids in the qualitative detection of aspirin effect in apparently healthy individuals post ingestion.

Why Test?
Not everyone benefits from the same dose of aspirin.

  • In aspirin treated patients, high levels of 11dhTxB2 are associated with increased risk of heart attack and cardiac death.
  • Patients who do not respond to aspirin are three times more likely to die of cardiovascular disease than those who respond well to aspirin.
  • Hyperlipidemia is associated with diminished response to aspirin.
  • 11dhTxB2 levels demonstrate a dose-related effect of aspirin treatment.
  • Diabetes may contribute to a diminished response to aspirin.
  • 11dhTxB2 levels have been shown to correlate with a Framingham Risk Score.

Who should get tested?
Apparently healthy individuals on aspirin therapy.

What are the advantages of ART™?

  • Measures production of thromboxane A2 (the target of aspirin therapy) to determine aspirin effect.
  • Uses a random urine sample. Morning specimen not a necessity.
  • Allows for individualized aspirin therapy.

Quick Links

Concierge Medicine Limited Time Offer History of Presidential Health